Some Dyax and Heartland Payment

I finally finished building a full position in Dyax (Ticker: DYAX) (~ 18% position) at an average price of $36.82. The play on Dyax right now is to acquire the CVRs on the cheap. The $4.00 payout from the CVR will be based on FDA approval by December 31, 2019 for their lead product DX-2930, which will be used for the prevention of type 1&2 HAE. I believe the company has a good shot in getting this drug approved by FDA prior to December 31, 2019. The phase 1 results were very good and the company is moving to initiate a phase 3 trial by the end of this year. We’ll see how this plays out in a few years…

 I took a stab today at Heartland Payments (Ticker: HPY) at $88.24 (~8.6% position). Bloomberg is reporting that Global Payments (Ticker: GPN) is in talks to acquire Heartland Payments. The market certainly likes this news as the stock of both companies shot up on the news. I really like this sector as the combination of these two companies makes perfect sense. In this space, building transaction volume is everything.